Trial Profile
A study of Thalidomide, Bendamustine, and Dexamethasone (BTD) vs Bortezomib, Bendamustine, and Dexamethasone (BBD) in patients with renal failure defined as a GFR below 30 mls/min
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Jul 2022
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Bortezomib (Primary) ; Bortezomib (Primary) ; Dexamethasone; Thalidomide
- Indications Myeloma
- Focus Pharmacodynamics
- Acronyms OPTIMAL
- Sponsors Janssen-Cilag
- 10 Dec 2019 Results presented at the 61st Annual Meeting and Exposition of the American Society of Hematology
- 02 Jul 2019 Planned End Date changed from 1 Jun 2020 to 31 Jul 2020.
- 29 Apr 2019 Status changed from completed to active, no longer recruiting.